Drug intelligence / Profile preview

MK2578

Development stage: Discontinued
Lead developer: Merck
Administration: Subcutaneous

Overview

MK2578 is a drug candidate that was developed by Merck Sharp & Dohme LLC for the treatment of anemia in patients with chronic kidney disease (CKD). It was investigated in Phase IIb clinical trials, where its efficacy and safety were compared to darbepoetin alfa, an erythropoiesis-stimulating agent. The drug was administered subcutaneously.

Other names: Erythropoietin biosimilarRecombinant PEG-erythropoietin biosimilar

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on MK2578.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK2578.

Explore the full profile